Skip to search formSkip to main contentSkip to account menu

adalimumab

Known as: antibody d2e7, Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer, Adalimumab [Chemical/Ingredient] 
A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
To the Editor: We report a case of new onset palmoplantar pustulosis and fulminant twenty nail psoriasis in a patient receiving… 
2012
2012
Clinical trials: Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid… 
2010
2010
To the Editor: Cutaneous manifestations are a common extraintestinal feature of inflammatory bowel disease (IBD). In fact, it has… 
2010
2010
A Case Report of Nephrotic Syndrome Due to Intake of Certolizumab Pegol in a Patient With Crohn's Disease 
2009
2009
Aim.  To assess the efficacy and safety profile of adalimumab in patients with severe, recalcitrant chronic plaque psoriasis, and… 
2009
2009
Auteur(s) : Elena Sotiriou, Zoe Apalla, Eustratios Vakirlis, Demetrios Ioannides First Dermatologic Department, Medical School… 
Review
2007
Review
2007
“Adalimumab is more effective” …? Worldwide, around one million patients have been treated with tumour necrosis factor (TNF… 
2007
2007
Dear Sir: The purpose of this letter is to report on the efficiency and advantages of the new anti-TNF therapy with adalimumab in…